TScan Therapeutics

TCRX

Market cap $68.7M

1.21 USD

+0.03

2.54%

At close Updated Jan 9, 4:00 PM EST

Pre-market

After hours

1.20

-0.01

0.83%

1 day

2.54%

5 days

16.35%

1 month

18.63%

3 months

-44.24%

6 months

-34.24%

Year to date

18.63%

1 year

-56.32%

5 years

-88.48%

10 years

-88.48%

About: TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

Employees: 148

Healthcare Biotechnology